0XOD.L - UroGen Pharma Ltd.

LSE - LSE Delayed Price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.76
52-week change 352.92%
S&P500 52-week change 32.72%
52-week high 313.75
52-week low 36.44
50-day moving average 39.91
200-day moving average 39.91

Share statistics

Avg vol (3-month) 32.48k
Avg vol (10-day) 31.78k
Shares outstanding 516.1M
Implied shares outstanding 6N/A
Float 819.65M
% held by insiders 19.97%
% held by institutions 169.61%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)31 Mar 2023

Profitability

Profit margin -164.16%
Operating margin (ttm)-116.39%

Management effectiveness

Return on assets (ttm)-35.49%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)67.98M
Revenue per share (ttm)2.96
Quarterly revenue growth (yoy)26.70%
Gross profit (ttm)56.7M
EBITDA -78.2M
Net income avi to common (ttm)-111.6M
Diluted EPS (ttm)-5.05
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)65.05M
Total cash per share (mrq)2.77
Total debt (mrq)100.31M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.80
Book value per share (mrq)-4.97

Cash flow statement

Operating cash flow (ttm)-89.37M
Levered free cash flow (ttm)-43.79M